Slide 1: Opioid Use Disorder: Zolunicant's Potential For Unmet Treatment Needs
MindMed Opioid Use Disorder: Zolunicant's Potential For Unmet Treatment Needs Thursday May 19, 2022 11:00 AM ET
Slide 2: Disclaimer
Disclaimer netomat conn porn Frt ening Saat ‘Masri conosco cn pret oy on inet rng tet hin he man of el th US Pt Seren Ln Bl of WS on thr ep ti ar anes concen bast red by or aor be "Santen" apa pop one oa nrg mp ron o naherrn pe ‘nema teas acta eta ancy ofa ea apt nt beter sere oo ior en ap creo eco
Slide 3: Business Highlights
Business Highlights Our mission is to deliver on the ic potential of and other novel targets to treat brain health disorders + Leader in developing psychedelic product candidates to treat brain health disorders + Diversified pipeline of clinical programs targeting significant unmet medical needs + I
Slide 4: Advancing Multiple Generations of Drug Candidates
Advancing Multiple G i of Drug Candidates cuassic PSYCHEDELICS 2ND GENERATION / ‘Spnizeo 38D GENERATION / Nees ©) MindMed + Clinical evidence of efficacy + Wellxcharacterized pharmacology + Accelerated development potenticl + Enhanced pharmacology + Overcome safety liabilities + Increased IP potenti
Slide 5: Research & Development Pipeline
Research & Development Pipeline 402 OMA DISCOVERY & EARLY DEVELOPMENT 3} MindMed KOL Webinar | May 2022
Slide 6: Opioid Withdrawal Program
veo incor Opie Wihdowot ©) MindMed KOL Webinar | Mey 2022
Slide 7: Key Milestones
Key Milestones | Phase 1 Topline Data Readout M M 0 Q2 2022 | Phase 1 Opioid W/D Study Initiation Q2 2022 | Phase 2a Zolunicant HCl Opioid W/D ESOE Readout Q1 2023 | Phase 2a (Part A) KOL Webinar | May 2022
Slide 8: Significant Unmet Need for Opioid Use Disorder (OUD) Treatments
Significant Unmet Need for Opioid Use Disorder (OUD) Treatments National Overdose Deaths from Opioids Number Among Al Age, by Gender 1999-2020 sm cme ns 68,630 seiner od 225% wars 89% sae 5) MindMed KOLWebinar | Moy202 8
Slide 9: Novel Mechanism to Address a Critical Gap in OUD Treatment
MM-110 | Novel Mechanism to Address a Critical Gap in OUD Treatment Opioid initiation Opioid Use Disorder (MM-t10-facilitated Supervised Withdrawal Medication Assisted Therapies (MAT) reduces cravings ‘medication adherence Stort MM-110 Induction to MAT ) MindMed OL Webinar | Mey 2002
Slide 10: Strong Preclinical Activity on Key Translational Outcomes
MM-110 | Strong Preclinical Activity on Key Translational Outcomes A single dose Reduction in Translational Markers of Opioid Withdrawal Reduction in Translational Markers of OUD MM-t10 dose (mg/kg) [Miv-10 dose (mg/g) &) MindMed KOL Webinor May 2022
Slide 11: Strong Preclinical Activity on Key Translational Outcomes
MM-110 | Strong Preclinical Activity on Key Translational Outcomes (Rho & ick 1998) Grooming ©) MindMed KOL Webinar | May2022 tt
Slide 12: Strong Preclinical Activity on Key Translational Outcomes
MM-110 | Strong Preclinical Activity on Key Translational Outcomes A single dose Dose of 40 mg/kg MM-110 in Rats (Glick 1996) ©) MindMed OL Webinar | May 2072
Slide 13: Phase 1 Study Results - Key Takeaways
Phase 1 Study Results - Key Takeaways ©) MindMed MM-110 (Zolunicant) is a Phase 2-Ready Asset Well-tolerated up to 500mg per day in SAD and 60mg per day in the MAD Linear PK maintained across the tested doses and frequencies Clinical effects align with potent CNS engagement QOD regimen aligns with p
Slide 14: Phase 1 SAD/MAD Dosing Cohorts
MM-110 | Phase 1 SAD/MAD Dosing Cohorts or placebo , = — + SAD well tolerated at doses up to S0Omg/day s + MAD well tolerated at doses up to 60mg/day ) MindMed
Slide 15: Phase 1 SAD/MAD Adverse Event Tables
MM-110 | Phase 1 SAD/MAD Adverse Event Tables ) MindMed KOL Webinar | Mey20z2 15
Slide 16: MM-110 Phase 1 SAD/MAD Adverse Event Summaries
MM-110 and MM: -110 | Phase 1 SAD/MAD Adverse Event Summaries ) MindMed only § TEAE 1 240) 4190) 240) 4080) © 120 120 700) 16 000) 00) 00)
Slide 17: Phase 1 SAD PK Curve
MM-110 | Phase 1 SAD PK Curve Treatment (Day t:2x250 mg) S / / V] / / Fg | I KOL Webinar | May 2022 ©) MindMed
Slide 18: Phase 1 MAD Comparison PK Curve
MM-110 | Phase 1 MAD Comparison PK Curve ©) MindMed KOL Webinar May 2022
Slide 19: Phase 2a Supervised Withdrawal in Opioid Use Disorder
MM-110 | Phase 2a Supervised Withdrawal in Opioid Use Disorder semen weagioe | magnon ort esto ste nett ese rte Primary Endpoint Interim Readout Primary Endpoint Mean SOWS-Gossop score over frst Mean SOWS-Gossop score over frst ' days of Treatment Phase ' days of Treatment Phase KOL Webinar | May 20